JP2014507116A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507116A5
JP2014507116A5 JP2013542189A JP2013542189A JP2014507116A5 JP 2014507116 A5 JP2014507116 A5 JP 2014507116A5 JP 2013542189 A JP2013542189 A JP 2013542189A JP 2013542189 A JP2013542189 A JP 2013542189A JP 2014507116 A5 JP2014507116 A5 JP 2014507116A5
Authority
JP
Japan
Prior art keywords
seq
pain
chain polypeptide
nos
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013542189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507116A (ja
JP6190723B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/062963 external-priority patent/WO2012075340A2/en
Publication of JP2014507116A publication Critical patent/JP2014507116A/ja
Publication of JP2014507116A5 publication Critical patent/JP2014507116A5/ja
Application granted granted Critical
Publication of JP6190723B2 publication Critical patent/JP6190723B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013542189A 2010-12-01 2011-12-01 抗ｎｇｆ組成物およびその使用 Expired - Fee Related JP6190723B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41883210P 2010-12-01 2010-12-01
US61/418,832 2010-12-01
PCT/US2011/062963 WO2012075340A2 (en) 2010-12-01 2011-12-01 Anti-ngf compositions and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016251053A Division JP2017079779A (ja) 2010-12-01 2016-12-26 抗ｎｇｆ組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2014507116A JP2014507116A (ja) 2014-03-27
JP2014507116A5 true JP2014507116A5 (https=) 2015-01-22
JP6190723B2 JP6190723B2 (ja) 2017-08-30

Family

ID=46162451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013542189A Expired - Fee Related JP6190723B2 (ja) 2010-12-01 2011-12-01 抗ｎｇｆ組成物およびその使用
JP2016251053A Abandoned JP2017079779A (ja) 2010-12-01 2016-12-26 抗ｎｇｆ組成物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016251053A Abandoned JP2017079779A (ja) 2010-12-01 2016-12-26 抗ｎｇｆ組成物およびその使用

Country Status (10)

Country Link
US (7) US9783602B2 (https=)
EP (2) EP2646468B1 (https=)
JP (2) JP6190723B2 (https=)
KR (2) KR20190112175A (https=)
CN (1) CN103619879A (https=)
AU (2) AU2011336470B8 (https=)
CA (1) CA2821515A1 (https=)
MX (1) MX359070B (https=)
NZ (1) NZ611076A (https=)
WO (1) WO2012075340A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
DK2710114T3 (da) * 2011-05-20 2021-12-06 H Lundbeck As Fremstilling med høj renhed af proteiner med multi-underenheder såsom antistoffer i transformerede mikrober såsom pichia pastoris
US10150968B2 (en) 2011-08-19 2018-12-11 Alderbio Holdings Llc Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
CA2932547C (en) * 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
CA2982861A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
WO2017157325A1 (zh) * 2016-03-18 2017-09-21 舒泰神（北京）生物制药股份有限公司 神经生长因子融合蛋白、制备方法及其用途
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3426288A4 (en) * 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3067835A1 (en) * 2017-06-22 2018-12-27 Apexigen, Inc. Anti-vista antibodies and methods of use
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
EP3645050A4 (en) * 2017-06-25 2021-08-11 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
CA3076662A1 (en) 2017-09-25 2019-03-28 Ecm Diagnostics, Inc. Methods for treating degenerative disc disease and chronic lower back pain
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
US10765630B2 (en) 2018-03-16 2020-09-08 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
CN108623687A (zh) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
CN113924315B (zh) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 抗β-NGF纳米抗体及其应用
CN117186219B (zh) * 2020-04-17 2024-07-12 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN116178541B (zh) * 2020-08-06 2025-09-30 熙源安健医药(北京)有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
US20230398232A1 (en) * 2020-09-28 2023-12-14 Navrogen, Inc. Composition and Use of Alternatively Formatted Anti-Mesothelin Antibodies for the Treatment of Cancer
AU2021356529A1 (en) * 2020-10-07 2023-06-15 Reiley Pharmaceuticals, Inc. Coxib-derived conjugate compounds and methods of use thereof
CN115433278A (zh) * 2021-06-05 2022-12-06 苏州缔码生物科技有限公司 结合cs1蛋白兔重组单克隆抗体及应用
CN120359243A (zh) * 2022-10-18 2025-07-22 昂科里斯庞斯公司 Lilrb2抗体产物和方法
CN121285385A (zh) * 2023-05-12 2026-01-06 金麦安博股份有限公司 能够与ox40结合的抗体、其变体及其用途
WO2024243049A2 (en) * 2023-05-19 2024-11-28 Ltz Therapeutics Inc. Antibodies and uses thereof
CN118440185B (zh) * 2024-05-22 2024-11-19 宁夏大学 抗bhv-1的重组兔单克隆抗体及双抗体夹心elisa试剂和应用
CN118465261B (zh) * 2024-07-09 2024-10-15 浙江康佰裕生物科技有限公司 一种检测逆转录病毒载体物理滴度的elisa试剂盒
CN118702814B (zh) * 2024-07-12 2026-03-06 麦里生物科技(上海)有限公司 一种抗ngf单克隆抗体及其应用

Family Cites Families (353)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4230691A (en) 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5683894A (en) 1988-04-29 1997-11-04 University Of California Recombinant nerve growth factor
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5656435A (en) 1989-08-28 1997-08-12 Takeda Chemical Industries, Ltd. Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US6506728B2 (en) 1990-09-25 2003-01-14 Genentech, Inc. Methods using a novel neurotrophic factor, NT-4
US6566091B1 (en) 1990-09-25 2003-05-20 Genentech, Inc. Neurotrophic factor
US5604202A (en) 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US6140120A (en) 1993-02-12 2000-10-31 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5908623A (en) 1993-08-12 1999-06-01 Cytotherapeutics, Inc. Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
EP0734438A4 (en) 1993-12-17 1998-12-23 Spinal Cord Society METHOD FOR INDUCING DNA SYNTHESIS IN NEURONES
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6024734A (en) 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US6291247B1 (en) 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
US5728803A (en) 1994-06-03 1998-03-17 Genentech, Inc. Pantropic neurotrophic factors
US7144983B1 (en) 1997-02-03 2006-12-05 Genentech, Inc. Pantropic neurotrophic factors
US5840576A (en) 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
US6271205B1 (en) 1994-09-21 2001-08-07 University Of Massachusetts Medical Center Cancer treatment by expression of differentiation factor receptor
US5759775A (en) 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US6096716A (en) 1994-12-12 2000-08-01 The Board Of Regents, The University Of Texas System Liposome-mediated transfection of central nervous system cells
US6211142B1 (en) 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5688911A (en) 1995-05-03 1997-11-18 Schneider; Rainer Trk neurotrophin binding motifs
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US5731284A (en) 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US20020090682A1 (en) 1995-10-23 2002-07-11 Tracy Willson Novel haemopoietin receptor and genetic sequences encoding same
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
US6406710B1 (en) 1996-01-16 2002-06-18 Nikos Panayotatos Protein occlusion for delivery of small molecules
WO1997026275A1 (en) 1996-01-16 1997-07-24 Nikos Panayotatos Protein occlusion for delivery of small molecules
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
GB9608335D0 (en) 1996-04-23 1996-06-26 Univ Kingston Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998032458A1 (en) 1997-01-23 1998-07-30 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
US6365373B2 (en) 1997-04-25 2002-04-02 Genentech, Inc. Nucleic acids encoding NGF variants
US7452863B1 (en) 1997-04-29 2008-11-18 Genentech, Inc. NGF variants
IL133708A0 (en) 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination thereof
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US5990129A (en) 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US5928174A (en) 1997-11-14 1999-07-27 Acrymed Wound dressing device
US7282482B2 (en) 1998-04-08 2007-10-16 The Regents Of The University Of California NGF for the prevention of demyelination in the nervous system
US20030096753A1 (en) 1998-04-09 2003-05-22 Robertson Alan George Simpson Therapeutic agent
GB9807781D0 (en) 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US6428579B1 (en) 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
AU6151899A (en) 1998-09-23 2000-04-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of treating chronic pain
US6506599B1 (en) 1999-10-15 2003-01-14 Tai-Wook Yoon Method for culturing langerhans islets and islet autotransplantation islet regeneration
US6680292B1 (en) 1998-11-20 2004-01-20 The Salk Institute For Biological Studies Pharmaceutical composition comprising ribavirin and growth factors and methods of use
US6927024B2 (en) 1998-11-30 2005-08-09 Genentech, Inc. PCR assay
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
HU229520B1 (en) 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US20020177120A1 (en) 1999-06-04 2002-11-28 Kathryn J. Elliott Assays for apotosis modulators
US20030152562A1 (en) 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7160924B2 (en) 2002-07-19 2007-01-09 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU7855900A (en) 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6548062B2 (en) 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
US20040058393A1 (en) 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
US7473555B2 (en) 2000-04-27 2009-01-06 Geron Corporation Protocols for making hepatocytes from embryonic stem cells
WO2001083796A2 (en) 2000-05-03 2001-11-08 University Of Washington Adenoviral vectors for tumor specific gene expression and uses thereof
ATE446366T1 (de) 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
EP1790344B1 (en) 2000-07-07 2011-02-23 Spectrum Pharmaceuticals, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US20020164333A1 (en) 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US6719970B1 (en) 2000-07-10 2004-04-13 Alkermes Controlled Therapeutics, Inc. Method of generating cartilage
WO2002003922A2 (en) 2000-07-11 2002-01-17 Lipps Binie V Synthetic peptide for neurological disorders
US20070122904A1 (en) 2000-09-29 2007-05-31 Unisearch Limited Method and apparatus for culturing cells
EP2351838A1 (en) 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Crosslinking agonistic antibodies
US20020128179A1 (en) 2000-12-01 2002-09-12 Tacon William C. Shaped microparticles for pulmonary drug delivery
US20020115173A1 (en) 2000-12-11 2002-08-22 Children's Medical Center Corporation Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity
US7169568B2 (en) 2000-12-18 2007-01-30 New York University Method for screening molecules that exert a neurotrophic effect through activation of neurotrophin receptors
DE10101546B4 (de) 2001-01-15 2005-04-28 Man Technologie Gmbh Verfahren zur Herstellung einer hochtemperaturfesten Faserverbundkeramik und so hergestellte Bauteile
US6602241B2 (en) 2001-01-17 2003-08-05 Transvascular, Inc. Methods and apparatus for acute or chronic delivery of substances or apparatus to extravascular treatment sites
WO2002057496A2 (en) 2001-01-18 2002-07-25 Socratech L.L.C. Gene expression profiling of endothelium in alzheimer's disease
US6485707B2 (en) 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6749845B2 (en) 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
US6596262B2 (en) 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6551578B2 (en) 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6475468B2 (en) 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US7029916B2 (en) 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
JP2004525930A (ja) 2001-03-23 2004-08-26 バイオファーム・ゲゼルシャフト・ツア・バイオテクノロジシェン・エントヴィックルング・フォン・ファーマカ・ミット・ベシュレンクテル・ハフツング 皮膚関連疾患の治療及び診断のためのＴＧＦ−βスーパーファミリーのサイトカインの使用
DE10291524D2 (de) 2001-04-06 2004-07-01 Anker Thorsten Verfahren zum Nachweis chronisch-demenzieller Erkrankungen, zugehörige Peptide und Nachweisreagenzien
CA2447986A1 (en) 2001-05-25 2002-12-05 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
JP2002348234A (ja) 2001-05-28 2002-12-04 Purotekku:Kk 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤
DK1401498T3 (da) 2001-05-30 2011-11-21 Genentech Inc Anti-NGF-antistoffer til behandlingen af forskellige sygdomme
WO2002102232A2 (en) 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
EP2574662B1 (en) 2001-08-22 2021-08-04 Maxcyte, Inc. Method for electroporation of biological samples
EP1458854B1 (en) 2001-12-21 2010-04-14 Mount Sinai Hospital Cellular compositions and methods of making and using them
US20050142539A1 (en) 2002-01-14 2005-06-30 William Herman Targeted ligands
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
CA2369810C (en) 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
WO2003066821A2 (en) 2002-02-04 2003-08-14 The Johns Hopkins University Molecules interacting with casl (mical) polynucleotides, polypeptides, and methods of using the same
US8491896B2 (en) 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
WO2003072753A2 (en) 2002-02-27 2003-09-04 Emory University Multimeric binding complexes
WO2003078567A2 (en) 2002-03-18 2003-09-25 Gamida-Cell Ltd. Methods of inducing differentiation in ex vivo expanded stem cells
US20040009589A1 (en) 2002-03-26 2004-01-15 Shulamit Levenberg Endothelial cells derived from human embryonic stem cells
US20060093589A1 (en) 2004-02-19 2006-05-04 Warrington Kenneth H Vp2-modified raav vector compositions and uses therefor
WO2004027019A2 (en) 2002-05-01 2004-04-01 University Of Florida Research Foundation, Inc. Improved raav expression systems for genetic modification of specific capsid proteins
US20030235580A1 (en) 2002-06-24 2003-12-25 Fen Zhang Amniotic membrane mediated delivery of bioactive molecules
WO2004003145A2 (en) 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US8263375B2 (en) 2002-12-20 2012-09-11 Acea Biosciences Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
US7745151B2 (en) 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
EP1545615A4 (en) 2002-10-04 2006-03-01 Rinat Neuroscience Corp METHODS OF TREATING CARDIAC ARRHYTHMIA AND PREVENTING DEATH OF CARDIAC ARRHYTHMIA USING NGF ANTAGONISTS
US20060185025A1 (en) 2002-10-04 2006-08-17 Kirin Beer Kabushiki Kaisha Human artificial chromosome (hac) vector
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
ZA200502612B (en) * 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
KR20050074492A (ko) 2002-10-22 2005-07-18 와라타 파마수티컬즈, 인크. 당뇨병의 치료
FR2846426B1 (fr) 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
US20050054097A1 (en) 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
AU2003287930A1 (en) 2002-12-20 2004-07-14 Neuronicon Aps Modulation of activity of neurotrophins
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
WO2004065560A2 (en) 2003-01-18 2004-08-05 Rinat Neuroscience Corp. Methods of screening for modulators of nerve growth factor
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP2191846A1 (en) 2003-02-19 2010-06-02 Rinat Neuroscience Corp. Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
US8545830B2 (en) 2003-03-24 2013-10-01 University Of Tennessee Research Foundation Multi-functional polymeric materials and their uses
US20060193825A1 (en) 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
KR20060003100A (ko) 2003-05-16 2006-01-09 블루 멤브레인스 게엠베하 생체적합성 코팅제를 포함하는 의료용 이식물
JP2007501021A (ja) 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
CA2530314A1 (en) 2003-07-10 2005-01-20 Marino Zerial Appl proteins as rab5 effectors
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
EP1500399A1 (en) 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
US20050027110A1 (en) 2003-07-24 2005-02-03 Michael Russell Drug delivery in the nervous system
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US20050085417A1 (en) 2003-10-16 2005-04-21 Thomas Jefferson University Compounds and methods for diagnostic imaging and therapy
US7846891B2 (en) 2003-10-17 2010-12-07 Massachusetts Institute Of Technology Self-assembling peptides for regeneration and repair of neural tissue
PT1678314E (pt) 2003-10-22 2012-11-27 Keck Graduate Inst Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
JP5039383B2 (ja) 2003-11-30 2012-10-03 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 免疫モジュレーションのための方法および薬剤ならびに免疫モジュレーターの同定方法
US20050123526A1 (en) 2003-12-01 2005-06-09 Medtronic Inc. Administration of growth factors for neurogenesis and gliagenesis
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
WO2005059515A2 (en) 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US20050143336A1 (en) 2003-12-30 2005-06-30 Board Of Regents, The University Of Texas System Methods and compositions for improved non-viral gene therapy
US8562988B2 (en) 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
JP5301152B2 (ja) 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
US20050233309A1 (en) 2004-04-19 2005-10-20 Hankins William D Kinetic process for the detection, diagnosis, processing, and monitoring of clonal cell populations
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
CN1997382A (zh) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
JP2008501725A (ja) 2004-06-10 2008-01-24 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ グリカンに特異的な受容体として機能するインテグリンを介したグリコシルホスファチジルイノシトールグリカンシグナル伝達
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
JP4940136B2 (ja) 2004-06-28 2012-05-30 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド キメラタンパク質およびその使用
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
MX2007001357A (es) 2004-08-02 2009-08-07 Childrens Medical Center Biomarcadores de plaquetas para cancer.
EP1773885B1 (en) 2004-08-05 2010-04-21 Genentech, Inc. Humanized anti-cmet antagonists
WO2006137836A2 (en) 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
KR100876771B1 (ko) 2004-08-17 2009-01-07 삼성전자주식회사 무선 통신 시스템에서 제어 정보 압축 방법과 스캐닝 정보 송수신 방법 및 장치
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
US20080213308A1 (en) 2004-09-14 2008-09-04 Nicholas Valiante Imidazoquinoline Compounds
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
US7629325B2 (en) 2004-10-11 2009-12-08 Technion Research & Development Foundation Ltd. Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy
US20060159666A1 (en) 2004-10-22 2006-07-20 Willing Alison E Method of potentiating inflammatory and immune modulation for cell and drug therapy
EP1815865A4 (en) 2004-11-08 2010-08-25 Ono Pharmaceutical Co THERAPEUTIC AGENT AGAINST DIABETES WITH A PROTEASE-INHIBITING COMPOUND
WO2006055841A2 (en) 2004-11-19 2006-05-26 University Of Florida Research Foundation, Inc. Indefinite culture of human adult glia without immortalization and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2006077441A1 (en) 2005-01-24 2006-07-27 Cambridge Antibody Technology Limited Specific binding members for ngf
DK1844337T3 (da) 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
WO2006081249A2 (en) 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
WO2006084173A1 (en) 2005-02-04 2006-08-10 The Johns Hopkins University Electroporation gene therapy gun system
WO2006088867A2 (en) 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
US20100172871A1 (en) 2005-02-17 2010-07-08 Flannery John G Muller Cell Specific Gene Therapy
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
AU2006220500A1 (en) 2005-03-09 2006-09-14 Board Of Regents, The University Of Texas System Novel hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
JP2008538112A (ja) 2005-03-23 2008-10-09 バイオ−ラッド ラボラトリーズ インコーポレーティッド 常磁性特性を持つ小粒子に結合した、多様な化学ライブラリー
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
JP2008538767A (ja) 2005-04-22 2008-11-06 ジェネンテック・インコーポレーテッド Ｃｄ２０抗体による認知症又はアルツハイマー病の治療方法
EP1885400A4 (en) 2005-06-02 2011-01-26 Galaxy Biotech Llc METHOD FOR THE TREATMENT OF BRAIN TUMORS BY ANTIBODIES
WO2006133164A2 (en) 2005-06-06 2006-12-14 Wyeth Anti-trkb monoclonal antibodies and uses thereof
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
DE602005012812D1 (de) 2005-06-13 2009-04-02 Primm Srl Heterodimere Peptide mit NGF Aktivität und deren Verwendung zur Behandlung von neurodegenerativen Krankheiten
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
WO2006138343A2 (en) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
KR20080068004A (ko) 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2267030A1 (en) 2005-08-25 2010-12-29 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
JP2009508970A (ja) 2005-09-21 2009-03-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 疼痛の局所造影および治療のためのシステム、組成物並びに方法
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
CN101360759A (zh) 2005-11-07 2009-02-04 哥本哈根大学 神经营养因子衍生的肽序列
EP1974018A4 (en) 2005-12-08 2010-01-27 Univ Louisville Res Found VSEL (VERY SMALL EMBRYONIC LIKE) STEM CELLS AND METHOD OF ISOLATING AND USE THEREOF
AU2006326870A1 (en) 2005-12-22 2007-06-28 Apollo Life Sciences Transdermal delivery of pharmaceutical agents
EP1971288B1 (en) 2005-12-30 2013-02-13 Neurotech USA, Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
US7342146B2 (en) 2006-01-11 2008-03-11 Industrial Technology Research Institute Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein
KR100784485B1 (ko) 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
US8163018B2 (en) 2006-02-14 2012-04-24 Warsaw Orthopedic, Inc. Treatment of the vertebral column
DK1988910T3 (en) 2006-02-28 2018-01-22 Kodiak Sciences Inc ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE-CONTAINING POLYMER CONJUGATES AND PREPARATION thereof
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
KR100746962B1 (ko) 2006-04-04 2007-08-07 한국과학기술연구원 온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도
WO2007127803A2 (en) 2006-04-25 2007-11-08 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
BRPI0711586A2 (pt) 2006-05-15 2011-11-16 Immunonomedics, Inc. método para tratamento de infecção por hiv em um indivìduo, método para imagem latente detectar ou diagnosticar a infecção por hiv em um indivìduo, composição
DK2021463T3 (en) 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Culture method to obtain a cloned population of antigen-specific B cells
US8623610B2 (en) 2006-05-22 2014-01-07 California Institute Of Technology Chondroitin sulfate binding proteins and modulators thereof
US20100003679A1 (en) 2006-06-09 2010-01-07 University Of Miami Assessment of cellular composition and fractional viability and uses thereof
US8475788B2 (en) 2006-06-14 2013-07-02 Stemnion, Inc. Methods of treating spinal cord injury and minimizing scarring
CA2658204A1 (en) 2006-07-07 2008-01-31 Kyowa Hakko Kirin Co., Ltd. Human artificial chromosome (hac) vector and human cell medicine comprising same
US20080132427A1 (en) 2006-07-21 2008-06-05 Yao Zhuang Cell systems and methods for detecting proliferation acitvity
EP1882697B1 (en) 2006-07-24 2010-04-21 Institut Pasteur Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
US8168169B2 (en) 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
EP2054529B1 (en) 2006-08-25 2014-03-26 Duke University Methods for in vivo identification of endogenous mrna targets of micrornas
US20090004742A1 (en) 2006-11-01 2009-01-01 Duke University Selection of antigen-specific t cells
GB0622688D0 (en) 2006-11-14 2006-12-27 Diosamine Dev Corp Novel compounds
US8648169B2 (en) 2006-12-05 2014-02-11 The Royal Institution For The Advancement Of Learning/Mcgill University Methods of use of Trk receptor modulators
US20080139790A1 (en) 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
EP3225251B1 (en) 2006-12-21 2020-02-12 H. Lundbeck A/S Modulation of activity of proneurotrophins
NZ577436A (en) 2006-12-22 2012-05-25 Genentech Inc Death receptor 6 (dr6) antagonist inhibiting the binding of dr6 to amyloid precursor protein (app), and uses thereof in treating neurological disorders
US8183219B2 (en) 2007-01-03 2012-05-22 Medtronic, Inc. Therapeuting compositions comprising an RNAi agent and a neurotrophic factor and methods of use thereof
US20100009997A1 (en) 2007-01-12 2010-01-14 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug
KR20090114430A (ko) 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
US7786267B2 (en) 2007-02-02 2010-08-31 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
WO2008101215A1 (en) 2007-02-16 2008-08-21 Varian Medical Systems Technologies, Inc. Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
US20080254047A1 (en) 2007-02-23 2008-10-16 Baylor Research Institute Activation of Human Antigen-Presenting Cells Through CLEC-6
MX2009008926A (es) 2007-02-23 2009-09-14 Baylor Res Inst Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
US20110268776A1 (en) 2007-04-25 2011-11-03 Schapira Jay N Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
HUE032563T2 (en) 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090232801A1 (en) 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
KR100968591B1 (ko) 2007-06-14 2010-07-08 한국과학기술연구원 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
US20080318314A1 (en) 2007-06-20 2008-12-25 Valentin Fulga Production from blood of cells of neural lineage
US20110038865A1 (en) 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
BRPI0815370B8 (pt) * 2007-08-10 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
AU2008295509A1 (en) 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US20110034383A1 (en) 2007-10-15 2011-02-10 Institut Pasteur Cxcl12 gamma a chemokine and uses thereof
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
EP2220125A4 (en) 2007-11-13 2010-12-29 Sapphire Energy Inc PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE
CN102131827A (zh) 2007-12-13 2011-07-20 葛兰素集团有限公司 用于肺部传递给药的组合物
RU2570559C2 (ru) 2007-12-17 2015-12-10 Пфайзер Лимитед Лечение интерстициального цистита
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
EP2292089A1 (en) 2008-01-11 2011-03-09 Astellas Pharma Inc. Model animal having both pain in testis or testis-related discomfort actions and frequent urination
WO2009097530A2 (en) 2008-01-30 2009-08-06 Baylor College Of Medicine Peptides that target dorsal root ganglion neurons
US9751947B2 (en) 2008-02-04 2017-09-05 Lay Line Genomics S.P.A. Antibodies and derivatives thereof
WO2009114702A2 (en) 2008-03-14 2009-09-17 Humanzyme Limited Recombinant production of authentic human proteins using human cell expression systems
EP2254886B1 (en) 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2009132656A2 (en) 2008-04-27 2009-11-05 H. Lundbeck A/S Design of specific ligands to sortilin
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
US8460657B2 (en) 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
CN101633694B (zh) 2008-07-24 2012-08-29 厦门北大之路生物工程有限公司 抗鼠神经生长因子(ngf)的多克隆抗体的制备方法及其应用
WO2010022225A1 (en) 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
CN102159204B (zh) 2008-09-19 2015-04-01 辉瑞公司 稳定的液体抗体制剂
WO2010036443A1 (en) 2008-09-26 2010-04-01 Eureka Therapeutics, Inc. Cell lines and proteins with variant glycosylation pattern
JP5879126B2 (ja) 2008-10-07 2016-03-08 ジン・トゥオＪＩＮ Ｔｕｏ 相転移ポリマーマイクロニードル
WO2010048446A2 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
US20100104652A1 (en) 2008-10-27 2010-04-29 University Of Arkansas Use of advanced nanomaterials for increasing sepecific cell functions
CN104357381A (zh) 2008-10-31 2015-02-18 辛西斯有限责任公司 用于活化干细胞的方法和装置
JP5746040B2 (ja) 2008-12-03 2015-07-08 ゲンマブ エー／エス 定常領域の中に改変を有する抗体変種
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
KR20110102921A (ko) 2008-12-31 2011-09-19 케이씨아이 라이센싱 인코포레이티드 조직 롤 스캐폴드
AU2010206374B2 (en) 2009-01-23 2013-01-17 Gloriana Therapeutics Sarl Improved cell lines and their use in encapsulated cell biodelivery
SG175436A1 (en) * 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
CN102482700A (zh) 2009-07-02 2012-05-30 葛兰素集团有限公司 多肽和治疗方法
US20110033463A1 (en) 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
JO3246B1 (ar) 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
US9155722B2 (en) 2009-09-18 2015-10-13 Protherics Salt Lake City, Inc. Reconstitutable reverse thermal gelling polymers
US8753621B2 (en) 2009-09-18 2014-06-17 Protherics Salt Lake City, Inc. BAB triblock polymers having improved release characteristics
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2011203890B2 (en) 2010-01-11 2013-05-30 Center For Molecular Medicine And Immunology Enhanced cytotoxicity of anti-CD74 and anti-HLA-DR antibodies with interferon-gamma
CN102892454B (zh) 2010-01-26 2016-01-20 迈克尔·A·埃文斯 用于去神经支配的方法、装置以及药剂
WO2011100637A1 (en) 2010-02-11 2011-08-18 The Board Of Trustees Of The Leland Stanford Junior University Markers for determination of patient responsiveness
PE20130203A1 (es) 2010-03-17 2013-03-24 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CA2794499A1 (en) 2010-04-01 2011-10-06 Immumomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
WO2011127141A1 (en) 2010-04-07 2011-10-13 Abbott Laboratories TNF-α BINDING PROTEINS
EP3345915B1 (en) 2010-04-12 2021-11-24 Somalogic, Inc. 5-position modified pyrimidines and their use
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
US9505829B2 (en) 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
JP6190723B2 (ja) 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US8668886B2 (en) 2011-04-24 2014-03-11 Therapeutic Proteins International, LLC Separative bioreactor
ES2704007T3 (es) 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
GB2504887B (en) 2011-05-06 2016-02-03 Nvip Pty Ltd Anti-Nerve growth factor antibodies and methods of preparing and using the same
CA2842492A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
PT2743348T (pt) 2011-08-11 2018-02-23 Astellas Pharma Inc Novo anticorpo anti-ngf humano
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
AP2014008145A0 (en) 2012-06-08 2014-12-31 Glenmark Pharmaceuticals Sa Humanized anti-trkA antibodies with animo acid substitutions
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease

Similar Documents

Publication Publication Date Title
JP2014507116A5 (https=)
CA2890263C (en) Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
CN104936614B (zh) 抗-PDGFR-β抗体及其使用
US9655964B2 (en) Bispecific antibodies directed against TNF-α and IL-17
JP6190723B2 (ja) 抗ｎｇｆ組成物およびその使用
CN102906114B (zh) 双特异性二价抗vegf/抗ang‑2抗体
JP2022028680A (ja) ＴＧＦβ１結合性免疫グロブリンおよびその使用
US9969812B2 (en) Anti human Notch4 antibody
CN106232626B (zh) 结合人大麻素1(cb1)受体的抗体
JP2021046414A (ja) 多価及び多重特異性ｄｒ５結合融合タンパク質
CN104203980B (zh) 抗‑大‑内皮素‑1(big‑et‑1)抗体及其用途
JP7637838B2 (ja) 抗ｔｉｇｉｔ抗体及びその適用
AU2013355324A1 (en) Blood-brain barrier (BBB) penetrating dual specific binding proteins
US20150158948A9 (en) Bispecific anti-cxcr7 immunoglobulin single variable domains
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
ES2687299T3 (es) Proteínas específicas para BAFF y B7RP1 y usos de las mismas
CA3154649A1 (en) Anti-stem cell factor antibodies and methods of use thereof in renal disease
CN115594762A (zh) 一种铁蛋白重链抗体及其用途
TWI834254B (zh) α-烯醇酶拮抗劑治療纖維化疾病之用途
JP7775345B2 (ja) 抗ｇｆｒａｌ抗体およびその使用
US20240059771A1 (en) Anti-cldn-18.2 antibody and use thereof
US20250127915A1 (en) Anti-cldn-18.2 antibody-drug conjugate and use thereof
JPWO2022253314A5 (https=)
US20250011441A1 (en) Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途